PropofolVet Multidose — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

PropofolVet Multidose

Active ingredient

Propofol

Application type

ANADA

Sponsor

Parnell Technologies Pty. Ltd.

Applications on record

1

First published

December 2, 2024

Adverse event reports

Source: openFDA VeDDRA

4,732

Reports mentioning this ingredient

March 14, 1997 – March 26, 2026

1,933

Classified serious

per reporter assessment

401

Lack of expected efficacy

resistance signal

18

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “PROPOFOL”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Death	377
Color, Abnormal	349
INEFFECTIVE, ANESTHESIA	305
Apnoea	253
Cardiac arrest	253
Bradycardia	206
Lack of efficacy - NOS	132
Convulsion	123
Contamination, Foreign Object	112
Cyanosis	109
Vomiting	85
Seizure NOS	84
Recovery prolonged	79
Hyperexcitation	76
Paddling	72
Tachycardia	72
Fever	65
Twitching	65
Vocalisation	53
Hypotension	53

Species affected

Source: openFDA VeDDRA

Dog 2,966 Cat 1,138 Other 22 Human 13 Turtle 4 Pig 4 Horse 2 Rabbit 2 Other Rodents 1 Alpaca 1 Wolf 1 Crustacea 1

Regulatory context

Abbreviated New Animal Drug Application (ANADA). A generic animal drug demonstrating bioequivalence, pharmaceutical equivalence and identical manufacturing criteria to the pioneer application. Veterinary generics have no formal therapeutic-equivalence coding system; they match the pioneer NADA specification instead.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient